Isomorphic Labs

Isomorphic Labs is an Alphabet subsidiary applying breakthrough AI — building on the AlphaFold lineage — to transform drug discovery. The company is developing a next-generation AI drug design engine and advancing an internal pipeline focused on oncology and immunology, alongside major pharmaceutical partnerships with Eli Lilly ($3B deal) and Novartis ($1.2B deal). In March 2025, Isomorphic raised $600M in its first external funding round, led by Thrive Capital.

Internal programs primarily in oncology and immunology

$600M+

Total raised

Next-generation AI drug design engine building on the AlphaFold lineage of protein structure prediction. The platform combines structure prediction, molecular generation, and property optimization to design drug candidates with unprecedented speed and accuracy.